Send us a text

Surfing NASH  delivers another wrap-up session on-site in Vienna in a real-time review of a truly thought-provoking EASL Congress 2023. The conversation features  impressions of Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green in a discussion focused on a range of topics covered at the meeting. Notably, the group touches on the highly anticipated nomenclature announcement, fascinating basic scientific and therapeutic insights and much more.

Listen on to learn more and stay tuned for a Part 2 of this exclusive coverage. If you have any question or interests around the event, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].

Stay Safe and Surf On!

This episode was generously sponsored by Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.